Skip to content
Open in App
Revolution Med logo

Revolution Med

web2

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targete...

Symbol · 1RVMD
Company profile

About

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

FDA approves RASONQUE for metastatic pancreatic adenocarcinoma

KEY STEP

On August 26, 2026, the U.S. FDA approved RASONQUE, or daraxonrasib, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

Roadmap reference
People

Company team

SJ

Sandra J. Horning

Independent Director

Company leadership profile.

EM

Elizabeth McKee Anderson

Independent Director

Company leadership profile.

LH

Lorence H. Kim

Independent Director

Company leadership profile.

FK

Franklin K. Clyburn

Independent Director

Company leadership profile.

MA

Mark A. Goldsmith

CEO, President & Chairman

Company leadership profile.

MD

Martin D. Burke

Co-Founder & Chairman of Scientific Advisory Board

Company leadership profile.

MA

Michael A. Fischbach

Academic Co-Founder & Member of Scientific Advisory Board

Company leadership profile.

KM

Kevan M. Shokat

Academic Co-Founder & Member of Scientific Advisory Board

Company leadership profile.

AA

Alexis A. Borisy

Lead Independent Director

Company leadership profile.

EM

Eric M. Gordon

Senior Advisor & Member of Scientific Advisory Board

Company leadership profile.

JA

Julian Adams

Senior Advisor & Member of Scientific Advisory Board

Company leadership profile.

JK

John Kuriyan

Senior Advisor & Member of Scientific Advisory Board

Company leadership profile.

TB

Trever Bivona

Senior Advisor & Member of Scientific Advisory Board

Company leadership profile.

TS

Thilo Schroeder

Independent Director

Company leadership profile.

SG

Sue Gail Eckhardt

Senior Advisor & Scientific Advisory Board Member

Company leadership profile.

FB

Flavia Borellini

Independent Director

Company leadership profile.

SP

Sushil Patel

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Revolution Med.

Orbitrum research

Experts evaluating Revolution Med

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment